Open Access

ARTICLE

Suppression of human papillomavirus type 16 E5 oncoprotein: A promising step in fostering the treatment of cervical cancer

NIMA HEMMAT¹, MOHAMMAD AMIN DOUSTVANDI¹, ZAHRA ASADZADEH¹, AHAD MOKHTARZADEH¹, BEHZAD BARADARAN^1,4,*, HOSSEIN BANNAZADEH BAGHI^1,2,3,*

1 Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2 Infectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
3 Department of Virology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
4 Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

* Corresponding Authors: Hossein Bannazadeh Baghi, ; Behzad Baradaran,

Oncology Research 2021, 29(2), 141-148. https://doi.org/10.32604/or.2022.023346

Received 20 April 2022; Accepted 13 June 2022; Issue published 13 July 2022

Abstract

Cervical cancer is a growing global disease in developing countries. Persistent infection with human papillomaviruses (HPV) is an essential causative agent in this type of cancer. Several studies demonstrate HPV E5 oncoprotein can impress the normal life cycle of HPV-infected cells by targeting some pivotal cellular signaling pathways, such as the epidermal growth factor receptor (EGFR) signaling pathway. In this study, we used E5-siRNA to knockdown that essential oncogene and considered the effect of E5 silencing on proliferation, apoptosis, cell cycle, apoptosis-related gene expression, and the initiator of the EGFR signaling pathway in cervical cancer cells. The results demonstrate that E5 plays an essential role in the proliferation and inhibited apoptosis in cervical cancer. Furthermore, silencing E5 reduces proliferation, increases apoptosis, and elevates related-genes expression of these malignant cells. Overall, E5 suppression may be appropriate for ameliorating cervical cancer progression.

---

Keywords

---